- Home
- BMEA vs FGB Comparison
BMEA vs FGB Comparison
Compare BMEA & FGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- FGB
- Stock Information
- Founded
- BMEA 2017
- FGB 2007
- Country
- BMEA United States
- FGB United States
- Employees
- BMEA N/A
- FGB N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- FGB Finance/Investors Services
- Sector
- BMEA Health Care
- FGB Finance
- Exchange
- BMEA Nasdaq
- FGB Nasdaq
- Market Cap
- BMEA 65.8M
- FGB 57.5M
- IPO Year
- BMEA 2021
- FGB N/A
- Fundamental
- Price
- BMEA $1.81
- FGB $4.11
- Analyst Decision
- BMEA Strong Buy
- FGB
- Analyst Count
- BMEA 10
- FGB 0
- Target Price
- BMEA $22.30
- FGB N/A
- AVG Volume (30 Days)
- BMEA 5.2M
- FGB 53.0K
- Earning Date
- BMEA 07-30-2025
- FGB 01-01-0001
- Dividend Yield
- BMEA N/A
- FGB 8.92%
- EPS Growth
- BMEA N/A
- FGB N/A
- EPS
- BMEA N/A
- FGB N/A
- Revenue
- BMEA N/A
- FGB N/A
- Revenue This Year
- BMEA N/A
- FGB N/A
- Revenue Next Year
- BMEA N/A
- FGB N/A
- P/E Ratio
- BMEA N/A
- FGB N/A
- Revenue Growth
- BMEA N/A
- FGB N/A
- 52 Week Low
- BMEA $1.29
- FGB $2.85
- 52 Week High
- BMEA $13.07
- FGB $3.74
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- FGB 55.64
- Support Level
- BMEA $2.24
- FGB $3.98
- Resistance Level
- BMEA $3.08
- FGB $4.17
- Average True Range (ATR)
- BMEA 0.40
- FGB 0.06
- MACD
- BMEA -0.03
- FGB -0.00
- Stochastic Oscillator
- BMEA 25.07
- FGB 50.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.